Hayden E. Klein

"We need to get rid of all obstacles that are getting in the way of the patient getting their care," said Bo Gamble, director of strategic practice initiatives at Community Oncology Alliance (COA).

An extended follow-up to a 2015 study further supports that beginning antiretroviral therapy (ART) earlier is linked to better long-term outcomes compared with delayed ART initiation.

Across 4 types of smoking status groups, nonalcoholic fatty liver disease (NAFLD) risk significantly increased among participants who saw an increase in body mass index (BMI) and decreased among participants whose BMI went down.

Only 18% of US adults with cardiovascular disease (CVD) and 26% of adults at risk for CVD use wearable health devices.

Sibel Blau, MD, president and CEO of the Quality Cancer Care Alliance (QCCA), talks about why QCCA and National Cancer Care Alliance (NCCA) launched Exigent Research.

Considerable research on diabetic ketoacidosis (DKA) risk has been published since the publication of a 2011 systematic review, warranting an updated analysis.

Tom Robinson, vice president of global access at JDRF, talks about the predictive modeling exercise used to develop and refine the Type 1 Diabetes (T1D) Index.

Pear Therapeutics announced positive real-world data for reSET, a prescription digital therapeutic (PDT) for substance use disorder.

In an interview, the section chief of hepatology at Rush University Medical Center discussed why the addition of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code K76.82 is necessary.

Pharmacists must take time to understand why patients are not adherent to HIV pre-exposure prophylaxis (PrEP) and what barriers exist, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.

Selected coverage from the Quality Cancer Care Alliance (QCCA) Summer 2022 National Leadership Summit, the National Comprehensive Cancer Network (NCCN) Fall Policy Summit, and the American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Researchers also found an improvement in specialized blood markers focusing on inflammation, endothelial dysfunction, and albumin function in patients receiving weekly albumin injection.

Kelly Price, US Head of Rare Disease at HRA Pharma, talks about the shifting preference for nonpharmacologic treatments.

HIV antiretroviral therapy has changed and improved dramatically since it first became available, said Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope.

According to Tom Robinson, vice president of global access at JDRF, the creation of the Type 1 Diabetes (T1D) Index was prompted by a lack of basic data on the condition, such as how many people are living with and affected by T1D.

A maternal health mobile app helped pregnant women learn more about delivery sanitation, tetanus vaccination, reproductive tract infection symptoms, HIV/AIDS testing, and iron tablet usage.

Chronic liver disease and pancreatitis were among the digestive diseases with high increases in incidence and mortality since 2000.

Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, explains why it's important for pharmacists to learn about and advocate for their patients who are transgender or gender nonbinary.

Chelsee Jensen, PharmD, senior pharmacy specialist at Mayo Clinic, talks about the importance of patient, provider, and nursing education as the US biosimilars landscape evolves.

Chester "Bernie" Good, MD, MPH, senior medical director of the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, talks about the evolution of value-based contracts.

Brian MacDonald, PharmD, senior director of specialty clinical strategy and innovation at Magellan Rx Management, explains how enhanced utilization management programs are implemented and can lead to cost avoidance for rare disease treatments.

Kelly Price, US Head of Rare Disease at HRA Pharma, argues proving the value of the prescription digital therapeutic (PDT) market may lead to better coverage of PDTs.

Kevin N. Astle, PharmD, assistant professor at University of South Florida Taneja College of Pharmacy, expands on HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline discussed at the Academy of Managed Care Pharmacy Nexus fall 2022 meeting.

Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, goes over his session to be presented at the fall meeting of AMCP Nexus 2022.

While 70% of youth engaged with the sickle cell disease (SCD) pain self-management program, only 30% of caregivers engaged with it.

Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine, discusses the findings and implications of his study on the efficacy of JZP-258 in patients with narcolepsy and cataplexy.

Individuals who were homozygous carriers of the PNPLA3 I148M genetic variant and reported excessive drinking and obesity had a 17.5 to 30.1 higher risk of progression to liver disease complications.

Tom Robinson, vice president of global access at JDRF, explains how to navigate the Type 1 Diabetes (T1D) Index and what data can be pulled from it.

David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, emphasizes the importance of patients with HIV and providers working together.

The smartphone app used data from a questionnaire and balance tests to give users an intuitive fall risk score ranging between 0 and 100, indicating low, medium, or high fall risk.